Literature DB >> 10866050

Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study.

D Tripathy1, M Carlsson, P Almgren, B Isomaa, M R Taskinen, T Tuomi, L C Groop.   

Abstract

Recently, a new stage in glucose tolerance, impaired fasting glucose (IFG) (fasting plasma glucose level of 6.1-6.9 mmol/l), was introduced in addition to impaired glucose tolerance (IGT) (2-h glucose level of 7.8-11.0 mmol/l). It is not clear whether IFG and IGT differ with respect to insulin secretion or sensitivity. To address this question, we estimated insulin secretion (by measuring both insulin levels and the ratio of insulin-to-glucose levels in 30-min intervals) and insulin sensitivity (by using the homeostasis model assessment [HOMA] index) from an oral glucose tolerance test (OGTT) in 5,396 individuals from the Botnia Study who had varying degrees of glucose tolerance. There was poor concordance between IFG and IGT: only 36% (303 of 840) of the subjects with IFG had IGT, whereas 62% (493 of 796) of the subjects with IGT did not have IFG. Compared with subjects with normal glucose tolerance (NGT), subjects with IFG were more insulin resistant (HOMA-insulin resistance [IR] values 2.64 +/- 0.08 vs. 1.73 +/- 0.03, P < 0.0005), had greater insulin responses during an OGTT (P = 0.0001), had higher waist-to-hip ratios (P < 0.005), had higher triglyceride and total cholesterol concentrations (P < 0.0005), and had lower HDL cholesterol concentrations (P = 0.0001). Compared with subjects with IFG, subjects with IGT had a lower incremental 30-min insulin-to-glucose area during an OGTT (13.8 +/- 1.7 vs. 21.7 +/- 1.7, P = 0.0008). Compared with subjects with IGT, subjects with mild diabetes (fasting plasma glucose levels <7.8 mmol/l) showed markedly impaired insulin secretion that could no longer compensate for IR and elevated glucose levels. A progressive decline in insulin sensitivity was observed when moving from NGT to IGT and to subjects with diabetes (P < 0.05 for trend), whereas insulin secretion followed an inverted U-shaped form. We conclude that IFG is characterized by basal IR and other features of the metabolic syndrome, whereas subjects with IGT have impaired insulin secretion in relation to glucose concentrations. An absolute decompensation of beta-cell function characterizes the transition from IGT to mild diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866050     DOI: 10.2337/diabetes.49.6.975

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  78 in total

1.  Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

Authors:  Y Takeda; Y Fujita; J Honjo; T Yanagimachi; H Sakagami; Y Takiyama; Y Makino; A Abiko; T J Kieffer; M Haneda
Journal:  Diabetologia       Date:  2011-11-10       Impact factor: 10.122

2.  Predictors of the development of impaired fasting glucose versus impaired glucose tolerance are partly different in men: a 6-year follow-up study.

Authors:  M E Piché; J P Després; A Pascot; A Nadeau; A Tremblay; S J Weisnagel; J Bergeron; S Lemieux
Journal:  Diabetologia       Date:  2004-01-29       Impact factor: 10.122

3.  The Gly1057Asp polymorphism in IRS-2 interacts with obesity to affect beta cell function.

Authors:  N Stefan; A Fritsche; F Machicao; O Tschritter; H U Häring; M Stumvoll; M Stumvogel
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

4.  Preliminary data on the association between waist circumference and insulin resistance in children without a previous diagnosis.

Authors:  Elena Rodríguez-Rodríguez; Carolina Palmeros-Exsome; Ana M López-Sobaler; Rosa M Ortega
Journal:  Eur J Pediatr       Date:  2010-07-31       Impact factor: 3.183

5.  Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity.

Authors:  J Kuhl; A Hilding; C G Ostenson; V Grill; S Efendic; P Båvenholm
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

6.  Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?

Authors:  Leigh Perreault; Bryan C Bergman; Mary C Playdon; Chiara Dalla Man; Claudio Cobelli; Robert H Eckel
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-03       Impact factor: 4.310

7.  Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obese mice.

Authors:  Hana Alkhalidy; Will Moore; Aihua Wang; Jing Luo; Ryan P McMillan; Yao Wang; Wei Zhen; Matthew W Hulver; Dongmin Liu
Journal:  J Nutr Biochem       Date:  2018-05-01       Impact factor: 6.048

8.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

9.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

10.  Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes.

Authors:  G W Mills; P J Avery; M I McCarthy; A T Hattersley; J C Levy; G A Hitman; M Sampson; M Walker
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.